ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1316

Long-Term Safety and Efficacy of 4-Weekly Certolizumab Pegol Combination and Monotherapy in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study

Roy Fleischmann1, Ronald F. van Vollenhoven2, Jiri Vencovsky3, Rieke Alten4, Owen Davies5, Christian Stach6, Marc de Longueville7, Brenda Van Lunen8 and Ernest Choy9, 1University of Texas Southwestern Medical Center at Dallas, Dallas, TX, 2Karolinska Institute, Stockholm, Sweden, 3Institute of Rheumatology, Prague, Czech Republic, 4Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, 5UCB Pharma, Slough, United Kingdom, 6UCB Pharma, Monheim, Germany, 7Global Medical Affairs, UCB Pharma, Brussels, Belgium, 8UCB Pharma, Raleigh, NC, 9Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, certolizumab pegol and rheumatoid arthritis, treatment

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose: Certolizumab pegol (CZP) has been shown to be efficacious and have an acceptable safety profile when administered every 4 weeks (Q4W) as monotherapy (FAST4WARD, NCT00548834) or in combination with methotrexate (MTX) (Study 014, NCT00544154) for the treatment of rheumatoid arthritis (RA).1,2 This post-hoc analysis evaluated long-term safety and efficacy of 400mg CZP Q4W monotherapy and in combination with MTX for RA over 5 years.

Methods: The open label extension (OLE) study (NCT00160693) enrolled patients (pts) who withdrew or completed the 24 week (Wk) FAST4WARD or 014 studies. The primary OLE objective was to monitor safety. Pts were permitted to take DMARDs in OLE. Pt retention rates and efficacy are reported up to Wk280 (5.4yrs) (last time point all sites open) and safety up to Wk364 (final data cut-point) of the OLE. Safety population included all pts who received CZP in OLE (patients completing or withdrawing early from either feeder study who entered OLE and those originally randomized to PBO in the double-blind phase [all pts N=402, all monotherapy pts N=126]). Analyzed efficacy population consisted of (1) FAST4WARD and 014 Wk 24 completers from CZP group who entered OLE (N=71; CZP completers) and (2) FAST4WARD completers from CZP group who entered OLE and did not receive MTX or another DMARD at any point (N=48; CZP monotherapy completers).

Results: 50% of the CZP monotherapy completers remained in OLE at Wk280 (Figure).  These retention rates were similar to all CZP completers (Figure). For all monotherapy pts, the event rates per 100-pt yrs (ERs) for all adverse events (323.4), injection site reactions (2.8), all serious AEs (16.5) and serious neoplasms (0.8) were lower than for all pts (416.4, 3.6, 24.4 and 1.6). ER of serious infections, AEs leading to withdrawal and AEs leading to death were low and similar between populations (Table). In CZP completers and CZP monotherapy completers, respectively, DAS28-3(CRP) mean (SD) change from feeder study baseline was -1.8 (1.2) and -1.9 (1.4) at OLE entry, and -3.0 (1.4) and -3.1 (1.6) at Wk280. HAQ mean (SD) change from feeder baseline for the same groups were -0.4 (0.5) and -0.6 (0.7) at OLE entry, and -0.5 (0.6) and -0.7 (0.8) at Wk280, respectively.

Conclusion:  Use of CZP 400mg Q4W monotherapy has been confirmed to have an acceptable long-term safety profile. Some AEs seem to be lower in the monotherapy subgroup than for all pts, but this requires confirmation as it could be a consequence of selection bias. Long-term CZP monotherapy is associated with similar improvement in disease activity and physical function to a population where the majority of pts received combination therapy. CZP monotherapy pts had a similar retention rate in the OLE to the overall population.

References: 1. Fleischmann R et al. Ann Rheum Dis. 2009;68:805-811; 2. Choy E et al. Accepted for publication in Rheumatology November 2011

 

 


Disclosure:

R. Fleischmann,

UCB,

2,

UCB,

5;

R. F. van Vollenhoven,

UCB,

2,

UCB,

5;

J. Vencovsky,

UCB,

5,

UCB,

8;

R. Alten,

UCB,

2,

UCB,

5,

UCB,

8;

O. Davies,

UCB,

1,

UCB,

3;

C. Stach,

UCB,

1,

UCB,

3;

M. de Longueville,

UCB,

3;

B. Van Lunen,

UCB,

1,

UCB,

3;

E. Choy,

UCB,

2,

UCB,

5,

UCB,

8.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-safety-and-efficacy-of-4-weekly-certolizumab-pegol-combination-and-monotherapy-in-rheumatoid-arthritis-5-year-results-from-an-open-label-extension-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies